OncoGenex' OGX-427 Progresses - Analyst Blog

By Zacks Equity Research,

Shutterstock photo

OncoGenex Pharmaceuticals, Inc. ( OGXI ) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study, Spruce, for the potential treatment of previously untreated advanced non-squamous non-small cell lung cancer (NSCLC).

The investigator-sponsored, randomized, double-blind, placebo-controlled phase II study will evaluate whether progression-free survival (PFS) outcomes can be improved by adding OGX-427 to carboplatin and pemetrexed therapy.

In the Spruce study, patients with non-squamous NSCLC will be randomized to receive carboplatin and pemetrexed therapy plus either OGX-427 or placebo.

Spruce is the fifth phase II study being conducted with OGX-427 after Borealis-1, Borealis-2, Pacific and OGX-427-PR01. The Borealis-1 study is designed to evaluate the survival benefit, safety and tolerability of combining OGX-427 with gemcitabine and cisplatin in the first-line treatment of patients with advanced bladder cancer. The Borealis-2 study is being conducted in patients suffering from advanced or metastatic bladder cancer whose disease has progressed following initial platinum-based chemotherapy treatment.

The Pacific study is evaluating the benefit of OGX-427 plus Johnson & Johnson's ( JNJ ) Zytiga in men with castration-resistant prostate cancer (CRPC) while OGX-427-PR01 is evaluating the benefit of OGX-427 plus prednisone in CRPC patients.

The most advanced candidate in OncoGenex' pipeline is custirsen, which is being studied for three indications under phase III trials, namely, Affinity (second-line CRPC), Enspirit (advanced NSCLC) and Synergy (chemotherapy - naive CRPC)

OncoGenex has a global collaboration and license agreement with Teva Pharmaceutical Industries Ltd.  ( TEVA ) for custirsen.

OncoGenex and Teva currently carry a Zacks Rank #3 (Hold). Currently, companies like UCB ( UCBJF ) look more attractive with a Zacks Rank #1 (Strong Buy).

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

ONCOGENEX PHARM (OGXI): Free Stock Analysis Report

TEVA PHARM ADR (TEVA): Free Stock Analysis Report

UCB SA (UCBJF): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
Referenced Stocks: JNJ , OGXI , PFS , TEVA , UCBJF

More from Zacks.com




Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com